Does long-term losartan-vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy

Blood Pressure

Volumn 15, Issue 4, 2006, Pages 198-206

  Christensen, Marina K ^a   Olsen, Michael H ^a   Wachtell, Kristian ^a   Tuxen, Christian ^a   Fossum, Eigil ^b   Bang, Lia E ^c   Wiinberg, Niels ^a   Devereux, Richard B ^d   Kjeldsen, Sverre E ^b   Hildebrandt, Per ^a   Rokkedal, Jens ^a   Ibsen, Hans ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF OSLO   (Norway)

^c NAESTVED HOSPITAL   (Denmark)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin II receptor antagonists; Beta receptor blockers; Hypertension; Left ventricular hypertrophy; Myocardial fibrosis; Procollagen

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; LOSARTAN; PROCOLLAGEN;

AGED; ARTICLE; BLOOD; BLOOD PRESSURE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBROSIS; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATENOLOL; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; PROCOLLAGEN;

EID: 34250304245     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050600962968     Document Type: Article

References (25)

1. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000;15:264-272 (Pubitemid 30496722)
2. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-35 (Pubitemid 30196635)
3. Diez J, Laviades C, Monreal I, Gil MJ, Panizo A, Pardo J. Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Am J Cardiol. 1995;76:14D-17D
4. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation. 1997;96:2488-2492 (Pubitemid 27451332)
5. Diez J, Lopez B, Gonzalez A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol. 2001; 16:328-335 (Pubitemid 33135220)
6. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension. 1999;34(4 Pt 2): 782-789 (Pubitemid 29501300)
7. Susic D, Varagic J, Frohlich ED. Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J Hypertens. 1999;17:1209-1215 (Pubitemid 29389570)
8. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez UJ, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286-291 (Pubitemid 32666949)
9. Brilla CG, Rupp H, Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz. 2003;28:744-753 (Pubitemid 38056939)
10. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez UJ. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002; 105:2512-2517 (Pubitemid 34568973)
11. Koffi I, Lacolley P, Kirchengaast M, Pomies JP, Laurent S, Benetos A. Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. Eur J Pharmacol. 1998;361:51-60 (Pubitemid 28522158)
12. Mancia G, Giannattasio C, Grassi G. Arterial distensibility in cardiovascular diseases. J Nephrol. 1998;11:284-288 (Pubitemid 29071217)
13. Franklin SS. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance? Curr Hypertens Rep. 2000;2:253-259
14. Olsen MH, Christensen MK, Wachtell K, Tuxen C, Fossum E, Bang LE, et al. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: A LIFE substudy. J Hum Hypertens. 2005;19:301-307 (Pubitemid 40514907)
15. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998;32:989-997 (Pubitemid 29001425)
16. Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H. A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Blood Press. 2000;9:132-139 (Pubitemid 30341431)
17. Palmieri V, Dahlof B, DeQuattro V, Sharpe N, Bella JN, de Simone G, et al. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement [see comments]. J Am Coll Cardiol. 1999;34:1625-1632 (Pubitemid 29528680)
18. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: Background and current applications of Doppler echocardiography. Part II. Clinical studies. Mayo Clin Proc. 1989;64:181-204 (Pubitemid 19080935)
19. Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke. 1993;24:1297-1304 (Pubitemid 23254630)
20. Cooper KE, Edholm OG, Mottram RF. The blood flow in skin and muscle of the human forearm. J Physiol. 1954;128:258-267
21. Utriainen T, Malmstrom R, Makimattila S, Yki JH. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia. 1995;38: 555-564
22. Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem. 1988;34:715-718
23. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation. 1995;91:1450-1456
24. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: Results of a randomized trial. Circulation. 2004;110:552-557 (Pubitemid 39031172)
25. Olsen MH, Wachtell K, Neland K, Bella JN, Rokkedal J, Dige-Petersen H, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press. 2005;14:177-183 (Pubitemid 41015717)